Page 1

Interim report first quarter 2021 Bactiguard Infection prevention | Saving lives Continued high activity in the first quarter - infection prevention a global sustainability issue First quarter 2021 • • • • • Revenues amounted to SEK 41.8 ( 48.1 ) million , a decrease by 13 % . Adjusted for currencies the decrease was 3 % . EBITDA amounted to SEK 1.9 ( 14.4 ) million with an EBITDA - margin of 5 % ( 30 % ) . Operating profit amounted to SEK -9.7 ( 3.9 ) million . Net loss for the period amounted to SEK -10.5 ( -11.2 ) million . Earnings per share amounted to SEK -0.31 ( -0.34 ) . Cash flow from operating activities amounted to SEK -0.9 ( -3.5 ) million corresponding to SEK -0.03 ( -0.11 ) per share . Covid - 19 impact During the first quarter , we saw continued recovery in the licensing business with BD and positive development for our BIP portfolio . Sales of BIP products is still affected by reduced general health care , due to Covid - 19 . The roll - out of vaccines will gradually have a positive impact and lead to a more normal situation in healthcare . At the same time , the global healthcare backlog grows and must be managed . In this context , we see a great need for infection prevention , which is positive for both the license- and BIP businesses . However , near - term developments are still difficult to assess . Key events during the first quarter • • • • Breakthrough in the licensing collaboration with Zimmer Biomet with a CE marking for trauma implants with Bactiguard's technology . Production has started and recurring license revenues are gradually being generated . A large randomized clinical study shows almost 70 % reduction in urinary tract infections with the Bactiguard technology . Bactiguard's disinfection- and wound care solution was launched in Greece . Apoteket AB includes Hydrocyn in their range . Covid - 19 related interim approval for Bactiguard's TempSensor Catheter in Canada . Continued strengthening of sales focus by recruiting a new Global Head of Sales . Cecilia Edström informed the Board that she will be leaving her post as CEO when a successor has been appointed . Key events after the end of the quarter • The wound care range will be introduced in Spain . Key figures Revenues2 , SEKM EBITDA³ , SEKM Jan - Mar 2021 Jan - Mar Full Year 2020 2020 RTM 2021 41.8 48.1 186.0 179.7 1.9 14.4 26.7 14.2 EBITDA margin³ , % 5 % 30 % 14 % 8 % Operating profit² , SEKM -9.7 3.9 -17.6 -31.2 Net profit / loss for the period² , SEKM -10.5 -11.2 -38.4 -37.8 Adjusted net profit / loss for the period 1,3 , SEKm -10.5 1.6 -27.5 -35.8 Earnings per share² , SEK -0.31 -0.34 -1.14 -1.13 Adjusted earnings per share 1,3 , SEK -0.31 0,05 -0.82 -1.07 Cash flow from operating activities² , SEKM -0.9 -3.5 0.7 3.3 Cash flow from operating activities per share³ , -0.03 -0.11 0.02 0.1 SEK Equity ratio³ , % 54 % 51 % 55 % 54 % Net debt³ , SEKM 258.3 241.5 254.1 258.3 1 The part of the purchase price for the acquisition of Vigilenz that consisted of shares is considered , for accounting purposes , as a financial instrument and the forward effect is thus reported as a financial item in the income statement and has affected net profit / loss for first quarter 2020 with SEK -12.8 million and full year 2020 with SEK -10.9 million . The adjustment is only affecting accounting and has no effect on cash flow . 2 Defined according to IFRS . 3 Alternative performance measure . For definition and reconciliation , see pages 17-18 . BACTIGUARD HOLDING AB ( publ ) Corporate registration number 556822-1187 1